This press release contains forward-looking statements related to Vertex, Alpine and the proposed acquisition of Alpine by Vertex (the “Transaction”) that are subject to risks, uncertainties and other factors. While Vertex believes the forward-looking statements contained in this communicatio...
After Alpine presented initial data for a kidney therapy in November 2023, its confidential data room became the most exclusive club in biotech.
compared to$13.7 billionas ofDecember 31, 2023. The reduction in Vertex’s cash, cash equivalents and marketable securities balance compared toDecember 31, 2023, was due to the cash consideration paid to acquireAlpine Immune Sciencesin the second quarter of 2024 and repurchases of our common...
The $4.4 billion AIP R&D charge for the Alpine acquisition equates to an impact of approximately $17 per share on Q2 GAAP and non-GAAP results and drove a non-GAAP loss per share of $12.83 in Q2 '24 compared to non-GAAP earnings per share of $3.89 in the second quarter of 2023. W...
Their latest acquisition was Alpine Immune Sciences on April 10, 2024. Date Investment Stage Companies Valuation Total Funding Note Sources 4/10/2024 Series A Alpine Immune Sciences $XXM $49M Acq - Pending 3 7/11/2022 Series D Subscribe to see more $XXM $XXM Subscribe to see more 10...
“We are privileged to partner with Vertex Service Partners, a leader in home improvement services,” said Mr. Schiffer. “Leading the search for their chief people officer and vice president of talent acquisition is an honor, as these pivotal roles will shape the...
For acquired IPR&D, we continue to expect approximately $4.6 billion for the year, including the Alpine asset acquisition charge recorded in the second quarter. Given that the Q2 2024 Alpine AIPR&D charge was not deductible for tax purposes, we expect the non-GAAP full year 2024 tax rate of...